Testing a new drug for advanced blood cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase study tests PEP07, a drug that blocks a cancer signal pathway (Checkpoint Kinase 1). It aims to see how well it works and how safely it can be given to people with certain advanced relapsed or refractory blood cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have advanced (relapsed or refractory) blood cancer: AML or mantle cell lymphoma with specific prior treatment history
- Your general health is good enough for treatment (ECOG performance status 0 to 2)
- Your kidneys and liver work well based on lab tests (creatinine clearance ≥ 50, and specific limits for AST/ALT/bilirubin)
- Your heart pumping strength is preserved (ejection fraction at least 50%) and your heart rhythm/QTc is not too abnormal
- You can have trial consent and required screening steps (including a COVID negative test and pregnancy testing if applicable)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called RPT1G for adults with acute myeloid leukemia or high-risk myelodysplastic syndromes that have not responded to standard treatments. The goal is to see if the drug is safe and if it shows signs of helping control the disease.
This study tests a new pill called PEP07 for people with advanced or metastatic solid tumors that have not responded to or cannot tolerate standard treatments. The goal is to see if PEP07 can help shrink or control the cancer.
This trial tests a new drug called PEP08 for people with advanced solid tumors that have a specific genetic change (MTAP deletion). It might be an option if standard treatments no longer work or cause too many side effects.
This trial tests a new drug called INCA036873, which targets CD70 on cancer cells, for people with advanced solid tumors or certain blood cancers that have not responded to prior treatments. The goal is to see if it is safe and effective against these tough-to-treat cancers.
This trial tests a new oral drug called EP102 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug is safe and works by targeting a protein called METTL3.
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.